Hamilton Thomas Edward, serving as a director at Larimar Therapeutics, Inc. (NASDAQ: LRMR), executed a significant purchase of company equity on July 6, 2026. The transaction involved the acquisition of 50,000 shares of the firm's common stock, with the total value of the deal reaching $166,890. The shares were obtained at a weighted average price of $3.3378 per share. The individual transaction prices for these shares varied between $3.33 and $3.35.
Following this acquisition, Mr. Hamilton's direct ownership of Larimar Therapeutics common stock increased to 714,798 shares. In addition to his direct holdings, he maintains an indirect stake of 159,433 shares through Post Edison, LLC. The transaction occurred as the company's stock was trading at $3.61, reflecting an increase from the previous close of $3.29. This price movement contributed to a market capitalization of $378 million for Larimar Therapeutics.
According to analysis from InvestingPro, LRMR appears to be undervalued at its current trading levels. An InvestingPro Tip highlights that the company maintains a balance sheet where cash holdings exceed debt. However, the analysis also notes that the firm is consuming its cash reserves at a rapid pace. The platform identifies four additional ProTips for investors seeking deeper insights into LRMR's prospects.
In regulatory developments, Larimar Therapeutics has submitted the first module of a rolling Biologics License Application (BLA) to the Food and Drug Administration for nomlabofusp, a treatment aimed at Friedreich’s ataxia. The company anticipates submitting the remaining modules during the second half of 2026. This timeline follows alignment with the FDA during a Type B multidisciplinary pre-BLA meeting.
Market analysts have recently initiated coverage on Larimar Therapeutics. H.C. Wainwright established a buy rating on the stock with a price target of $10.00, emphasizing the company's planned BLA submission for accelerated approval. JPMorgan also initiated coverage with an Overweight rating and a price target of $9.00, focusing on Larimar’s lead asset, nomlabofusp.
Larimar plans to host an investor event to discuss updates on its clinical development program for nomlabofusp. The event will provide a regulatory update and data from the ongoing long-term open-label study. These developments underscore Larimar's continued efforts toward obtaining accelerated approval for its treatment. The stock was reported at $3.61 with a change of +0.200 (+5.87%) at 15:59:59 USD. After hours trading showed the stock at $3.789 with a change of +0.179 (+4.97%) at 16:35:17. The article notes that the content was generated with the support of AI and reviewed by an editor.
InvestingPro's ProPicks AI evaluates LRMR monthly against thousands of alternatives using over 100 financial metrics. The system previously identified Siemens Energy (+231.5%) and Sandisk (+189%) before broader market recognition. The platform poses whether LRMR could be the next opportunity or if better prospects exist in the same sector. A July sale offering 60% off InvestingPro is also noted.